Cargando…
Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy
Vanishing white matter (VWM) disease is an autosomal genetic leukodystrophy caused by mutations in subunits of eukaryotic translation initiation factor 2B (eIF2B). The clinical symptoms exhibit progressive loss of white matter in both hemispheres of the brain, accompanied by motor functions deterior...
Autores principales: | Atzmon, Andrea, Herrero, Melisa, Sharet-Eshed, Reut, Gilad, Yocheved, Senderowitz, Hanoch, Elroy-Stein, Orna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153319/ https://www.ncbi.nlm.nih.gov/pubmed/30279648 http://dx.doi.org/10.3389/fnmol.2018.00336 |
Ejemplares similares
-
The Energy Status of Astrocytes Is the Achilles’ Heel of eIF2B-Leukodystrophy
por: Herrero, Melisa, et al.
Publicado: (2021) -
A reliable computational workflow for the selection of optimal screening libraries
por: Gilad, Yocheved, et al.
Publicado: (2015) -
Evaluation of the endoplasmic reticulum-stress response in eIF2B-mutated lymphocytes and lymphoblasts from CACH/VWM patients
por: Horzinski, Laetitia, et al.
Publicado: (2010) -
Effective extraction of polyribosomes exposes gene expression strategies in primary astrocytes
por: Mandelboum, Shir, et al.
Publicado: (2023) -
Core protocol development for phase 2/3 clinical trials in the leukodystrophy vanishing white matter: a consensus statement by the VWM consortium and patient advocates
por: Schoenmakers, Daphne H., et al.
Publicado: (2023)